Pfizer and BioNTech launch study of omicron vaccine, and FDA halts use of two COVID antibody treatments

One day after the U.S. Food and Drug Administration said it's halting the use of antibody drugs as COVID-19 treatments because they don't work on the highly contagious omicron variant, Pfizer and German partner BioNTech announced they are launching a trial to evaluate an omicron-based vaccine in healthy adults aged 18 to 55.